McDonald’s and CVS: why investors are waiting on earnings to confirm the “cheap” narrative

A market commentary published Monday framed upcoming earnings as the test for two widely followed consumer names: CVS Health and McDonald’s. The piece leaned on the idea that both stocks are priced for skepticism, pointing to Jim Cramer’s remarks that CVS was “too cheap to ignore” and to McDonald’s being at its cheapest level since 2014, at least in terms of how the shares currently trade versus past history.

From there, the thrust is less about valuation slogans and more about what management will say when the numbers arrive. For CVS, the critical question is whether underlying demand and pricing power hold up across its retail and pharmacy operations, and whether any cost pressures show up more sharply than investors expect. CVS earnings can also hinge on trends in pharmacy benefit services, including how many prescriptions are being filled and the economics of reimbursement.

For McDonald’s, the market note framed the timing as particularly consequential because the stock’s valuation positioning implies a lot of bad news is already reflected. That makes the upcoming report a direct check on whether same-store sales trends are stabilizing or improving, and whether margin performance can withstand labor costs, food and packaging expenses, and the intensity of promotional activity.

In both cases, “cheap” can describe very different situations. A stock can trade at a discount because growth is uncertain, because margins are under threat, or because the business model is facing structural pressure. Alternatively, shares can appear inexpensive if near-term fears have driven the market to price in more deterioration than ultimately occurs. The earnings report is the closest thing investors have to a truth serum, because it forces the company to reconcile volumes, pricing, and costs in a single set of results.

The commentary’s emphasis on what investors should watch underscores a common pattern for retailers and consumer services: headline revenue alone often does not settle the debate. Investors typically focus on comparable sales or equivalent measures, customer traffic and ticket trends where disclosed, and the drivers behind operating margin. They also look for guidance language that clarifies whether a business is working through one-time issues or if weaker conditions are persisting.

Sector context matters here. Consumer-facing companies have faced a prolonged balancing act between demand resilience and expense inflation. When consumers become more value-conscious, companies may need heavier promotions to sustain traffic, which can pressure margins even if sales volume holds. That is why earnings calls for both CVS and McDonald’s tend to carry extra weight: investors want evidence that the company can either defend pricing and mix or compensate via cost management.

It is also worth noting what the post did not provide in the information available for this story. The market note, as summarized here, did not lay out specific quarterly figures, forecasts, or detailed guidance elements. It focused on the “cheap” characterization and on the idea that the upcoming earnings releases will either validate that view or expose risks that remain underappreciated.

Looking ahead, the immediate watch items for investors are the companies’ first read-outs of demand and profitability, plus any forward-looking commentary about the remainder of the fiscal quarter or year. For CVS, attention will likely remain on pharmacy and services performance and how costs are trending. For McDonald’s, investors will likely watch comparable sales momentum, margin resilience, and whether management’s outlook suggests the current environment is improving or stabilizing only temporarily. Whether “too cheap to ignore” turns into a durable thesis will depend on how those details line up with expectations.